Skip to main content

Table 1 Demographics and baseline characteristics (ASaT population)

From: Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy regimens: a subgroup analysis from a randomized clinical trial of response in subjects by cancer type

  Fosaprepitant regimen Control regimen
GI or colorectal cancers
(n = 135)
Lung cancer
(n = 130)
Breast cancer
(n = 110)
Gynecologic cancer
(n = 81)
GI or colorectal cancers
(n = 132)
Lung cancer
(n = 124)
Breast cancer
(n = 121)
Gynecologic cancer
(n = 71)
Age, years
 Median (range) 62 (24–85) 65 (36–82) 57 (28–78) 58 (31–88) 60 (23–88) 65 (38–82) 54 (28–81) 56 (24–78)
Age group, n (%)  
  < 50 years 21 (15.6) 7 (5.4) 37 (33.6) 25 (30.9) 21 (15.9) 5 (4.0) 39 (32.2) 24 (33.8)
  ≥ 50 years 114 (84.4) 123 (94.6) 73 (66.4) 56 (69.1) 111 (84.1) 119 (96.0) 82 (67.8) 47 (66.2)
Sex, n (%)
 Male 86 (63.7) 90 (69.2) 1 (0.9) 0 76 (57.6) 90 (72.4) 0 0
 Female 49 (36.3) 40 (30.8) 109 (99.1) 81 (100) 56 (42.4) 34 (27.4) 121 (100) 71 (100)
History of motion sickness, n (%) 8 (5.9) 5 (3.8) 5 (4.5) 8 (9.9) 3 (2.3) 4 (3.2) 12 (9.9) 9 (12.7)
History of emesis during pregnancy, n (%) 11 (8.1) 7 (5.4) 24 (21.8) 15 (18.5) 15 (11.4) 6 (4.8) 23 (19.0) 15 (21.1)
History of alcohol use, n (%) 69 (51.1) 68 (52.3) 35 (31.8) 30 (37.0) 58 (43.9) 67 (54.0) 41 (33.9) 21 (29.6)
Chemotherapy regimen, n (%)a n = 135 n = 129 n = 110 n = 81 n = 132 n = 125 n = 121 n = 71
 Single day 28 (20.7) 108 (83.7) 100 (90.9) 81 (100) 21 (15.9) 109 (87.2) 110 (90.9) 69 (97.2)
 Multiple day 105 (77.8) 18 (14.0) 0 0 109 (82.6) 14 (11.2) 0 2 (2.8)
  1. ASaT all-subjects-as-treated, GI gastrointestinal
  2. aBased on the intention-to-treat population